Protembis Announces Completion of 20 Cases in European CE Mark Study With the ProtEmbo Cerebral Protection System financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
Researchers develop novel antibody fragments against SARS coronavirus-2
An international research team led by the University of Bonn (Germany) has identified and further developed novel antibody fragments against the SARS coronavirus-2. These nanobodies are much smaller than the classic antibodies used to treat US President Donald Trump, for example.
They therefore penetrate the tissue better and can be produced more easily in larger quantities. The researchers at the University Hospital Bonn have also combined the nanobodies into potentially particularly effective molecules. These attack different parts of the virus simultaneously. The approach could prevent the pathogen from evading the active agent through mutations. The results are published in the journal Science.
55 researchers each awarded €150,000 ERC grants
The Proof of Concept grants will enable researchers to explore the commercial or societal potential of their work.
The European Research Council (ERC) has awarded 55 researchers with Proof of Concept grants worth €150,000 each.
Projects by these researchers include a new low-cost test for Covid-19, a way to help develop new medicines to treat blindness, and further improvements to a clean energy producing technology.
The latest funding announcement, totalling €8.25m, brings the total number of ERC Proof of Concept grants in 2020 to 166, with funding going to researchers working in 21 different countries.
Mariya Gabriel, European commissioner for innovation, research, culture, education and youth, said the grants demonstrate how frontier research results can be used to benefit society and industry.
SMA Patients No Longer Doomed If Diagnosed Early
It is necessary to correctly evaluate which children can be treated with the approved drugs, says Dr. Soyhan Bagci. Gene therapy for spinal muscular atrophy (SMA) patients is effective for infants whose symptoms have never started or have just started, according to a pediatric and neonatal intensive care physician. After gene therapy is applied to children who are connected to a respiratory device and cannot walk, it is unfortunately not possible for them to leave the breathing apparatus, start running and return to normal life, Dr. Soyhan Bagci from Rheinische Friedrich-Wilhelms University in Bonn, Germany told Anadolu Agency.